Spirooxindole MDM2-p53 Inhibitors for Metabolic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing MDM2-p53 inhibitors face challenges in effectively inhibiting the protein-protein interaction, exhibit poor metabolic stability, and are prone to epimerization, limiting their therapeutic potential in cancer treatment.
Innovation Solution
Development of novel spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds that inhibit the MDM2-p53 interaction with high potency, good selectivity against p53 mutant cell lines, and improved chemical stability, including compounds of formula (I) with specific substituents and structural complexity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing MDM2-p53 inhibitors are used to block protein-protein interaction, then p53 reactivation is achieved, but metabolic stability is poor and epimerization occurs
Solution Approach 1:
The patent modifies the chemical structure of MDM2-p53 inhibitors by changing parameters such as introducing deuterium atoms, adjusting substituent groups (R1-R7), and modifying the core scaffold to improve metabolic stability while maintaining the ability to block the MDM2-p53 interaction and reactivate p53
Solution Approach 2:
The invention creates composite molecular structures combining the spirooxindole core with various substituted groups including aromatic rings, heterocycles, and alkyl chains, forming complex inhibitor molecules that achieve both target binding and metabolic stability
2Reliability
If existing MDM2-p53 inhibitors are used to inhibit protein-protein interaction, then p53 reactivation is achieved, but chemical stability is poor due to epimerization
Solution Approach 1:
The patent introduces deuterium substitution and modifies stereochemical configurations at key positions (such as the spiro carbon and adjacent chiral centers) to prevent epimerization while preserving the inhibitor's ability to bind MDM2 and reactivate p53
Solution Approach 2:
The invention converts the problematic epimerization tendency into a design constraint that guides the development of more stable analogs, where the knowledge of epimerization pathways informs the selection of rigidifying substituents and deuterium placement to lock the desired configuration
3Ease of manufacture
If simple MDM2-p53 inhibitor structures are used, then synthesis is easier, but inhibitory potency is insufficient
Solution Approach 1:
The patent divides the inhibitor molecule into distinct functional segments: a core spirooxindole binding motif, aromatic substituents for hydrophobic interactions, and polar groups for hydrogen bonding, allowing modular synthesis while achieving high potency through optimized segment arrangement
Solution Approach 2:
The invention extends simple two-dimensional aromatic rings into three-dimensional structures such as fused ring systems, bridged frameworks, and stereocenter-rich configurations that provide additional binding interactions and enhance potency without dramatically increasing synthetic complexity
Data Source
AI summary
The present invention encompasses intermediates for preparing compounds of formula (I)wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.